Ptc Therapeutics, Inc. (PTCT)

$35.37

-1.06

(-2.91%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $34.65
    $36.05
    $35.37
    downward going graph

    2.04%

    Downside

    Day's Volatility :3.88%

    Upside

    1.89%

    downward going graph
  • $17.53
    $40.69
    $35.37
    downward going graph

    50.44%

    Downside

    52 Weeks Volatility :56.92%

    Upside

    13.07%

    downward going graph

Returns

PeriodPtc Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
19.68%
7.5%
0.0%
6 Months
27.93%
6.9%
0.0%
1 Year
81.6%
20.9%
0.0%
3 Years
0.68%
21.0%
-21.1%

Highlights

Market Capitalization
2.9B
Book Value
- $12.75
Earnings Per Share (EPS)
-6.31
PEG Ratio
0.81
Wall Street Target Price
38.85
Profit Margin
-53.25%
Operating Margin TTM
-17.87%
Return On Assets TTM
-7.39%
Return On Equity TTM
-7740.12%
Revenue TTM
900.5M
Revenue Per Share TTM
11.84
Quarterly Revenue Growth YOY
-12.7%
Gross Profit TTM
2.6M
EBITDA
12.7M
Diluted Eps TTM
-6.31
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.07
EPS Estimate Next Year
-3.9
EPS Estimate Current Quarter
-1.05
EPS Estimate Next Quarter
-1.44

Analyst Recommendation

Buy
    50%Buy
    30%Hold
    20%Sell
Based on 20 Wall street analysts offering stock ratings for Ptc Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
5
5
Hold
6
6
7
Sell
4
8
8

Analyst Forecast

What analysts predicted

Upside of 9.84%

Current $35.37
Target $38.85

Company Financials

FY18Y/Y Change
Revenue
264.7M
↑ 36.19%
Net Income
-128.1M
↑ 62.13%
Net Profit Margin
-48.38%
↓ 7.74%
FY19Y/Y Change
Revenue
307.0M
↑ 15.96%
Net Income
-251.6M
↑ 96.42%
Net Profit Margin
-81.95%
↓ 33.57%
FY20Y/Y Change
Revenue
380.8M
↑ 24.04%
Net Income
-438.2M
↑ 74.17%
Net Profit Margin
-115.07%
↓ 33.12%
FY21Y/Y Change
Revenue
538.6M
↑ 41.45%
Net Income
-523.9M
↑ 19.57%
Net Profit Margin
-97.27%
↑ 17.8%
FY22Y/Y Change
Revenue
698.8M
↑ 29.75%
Net Income
-559.0M
↑ 6.7%
Net Profit Margin
-80.0%
↑ 17.27%
FY23Y/Y Change
Revenue
937.8M
↑ 34.2%
Net Income
-626.6M
↑ 12.09%
Net Profit Margin
-66.81%
↑ 13.19%
Q1 FY23Q/Q Change
Revenue
220.4M
↑ 31.64%
Net Income
-139.0M
↓ 18.68%
Net Profit Margin
-63.05%
↑ 39.03%
Q2 FY23Q/Q Change
Revenue
213.8M
↓ 2.98%
Net Income
-198.9M
↑ 43.12%
Net Profit Margin
-93.02%
↓ 29.97%
Q3 FY23Q/Q Change
Revenue
196.6M
↓ 8.06%
Net Income
-133.0M
↓ 33.14%
Net Profit Margin
-67.64%
↑ 25.38%
Q4 FY23Q/Q Change
Revenue
307.1M
↑ 56.2%
Net Income
-155.8M
↑ 17.16%
Net Profit Margin
-50.74%
↑ 16.9%
Q1 FY24Q/Q Change
Revenue
210.1M
↓ 31.57%
Net Income
-91.6M
↓ 41.22%
Net Profit Margin
-43.58%
↑ 7.16%
Q2 FY24Q/Q Change
Revenue
186.7M
↓ 11.14%
Net Income
-99.2M
↑ 8.3%
Net Profit Margin
-53.12%
↓ 9.54%
FY18Y/Y Change
Total Assets
1.1B
↑ 185.77%
Total Liabilities
768.5M
↑ 226.72%
FY19Y/Y Change
Total Assets
1.6B
↑ 45.08%
Total Liabilities
1.0B
↑ 33.96%
FY20Y/Y Change
Total Assets
2.2B
↑ 36.0%
Total Liabilities
1.7B
↑ 67.69%
FY21Y/Y Change
Total Assets
1.9B
↓ 12.24%
Total Liabilities
1.9B
↑ 12.18%
FY22Y/Y Change
Total Assets
1.7B
↓ 11.99%
Total Liabilities
2.1B
↑ 5.99%
FY23Y/Y Change
Total Assets
1.9B
↑ 11.58%
Total Liabilities
2.7B
↑ 32.59%
Q1 FY23Q/Q Change
Total Assets
1.6B
↓ 5.67%
Total Liabilities
2.1B
↑ 0.67%
Q2 FY23Q/Q Change
Total Assets
1.3B
↓ 16.83%
Total Liabilities
1.9B
↓ 7.21%
Q3 FY23Q/Q Change
Total Assets
1.3B
↓ 5.85%
Total Liabilities
1.9B
↑ 0.69%
Q4 FY23Q/Q Change
Total Assets
1.9B
↑ 51.06%
Total Liabilities
2.7B
↑ 40.97%
Q1 FY24Q/Q Change
Total Assets
1.8B
↓ 5.97%
Total Liabilities
2.7B
↓ 1.4%
Q2 FY24Q/Q Change
Total Assets
1.9B
↑ 7.08%
Total Liabilities
2.9B
↑ 7.94%
FY18Y/Y Change
Operating Cash Flow
-27.6M
↑ 174.68%
Investing Cash Flow
-42.6M
↓ 424.87%
Financing Cash Flow
131.6M
↑ 197.55%
FY19Y/Y Change
Operating Cash Flow
-98.6M
↑ 256.86%
Investing Cash Flow
-387.2M
↑ 808.73%
Financing Cash Flow
613.2M
↑ 366.07%
FY20Y/Y Change
Operating Cash Flow
-194.1M
↑ 96.75%
Investing Cash Flow
-561.5M
↑ 45.01%
Financing Cash Flow
668.7M
↑ 9.05%
FY21Y/Y Change
Operating Cash Flow
-251.3M
↑ 29.51%
Investing Cash Flow
219.2M
↓ 139.03%
Financing Cash Flow
20.9M
↓ 96.88%
FY22Y/Y Change
Operating Cash Flow
-356.7M
↑ 41.91%
Investing Cash Flow
290.2M
↑ 32.39%
Financing Cash Flow
168.0M
↑ 704.48%
Q1 FY23Q/Q Change
Operating Cash Flow
-29.5M
↓ 82.23%
Investing Cash Flow
-29.0M
↓ 189.31%
Financing Cash Flow
4.1M
↓ 98.65%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.1M
↓ 52.12%
Investing Cash Flow
-23.8M
↓ 18.01%
Financing Cash Flow
18.5M
↑ 350.9%

Technicals Summary

Sell

Neutral

Buy

Ptc Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ptc Therapeutics, Inc.
Ptc Therapeutics, Inc.
11.04%
27.93%
81.6%
0.68%
9.18%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.06%
10.55%
30.05%
89.27%
274.48%
Novo Nordisk A/s
Novo Nordisk A/s
-12.62%
-6.24%
35.65%
145.66%
372.59%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.37%
82.34%
59.06%
41.03%
258.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.23%
13.76%
34.75%
162.16%
172.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ptc Therapeutics, Inc.
Ptc Therapeutics, Inc.
NA
NA
0.81
-5.07
-77.4
-0.07
NA
-12.75
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.85
27.85
1.43
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.39
40.39
1.82
3.45
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ptc Therapeutics, Inc.
Ptc Therapeutics, Inc.
Buy
$2.9B
9.18%
NA
-53.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.9B
274.48%
27.85
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$531.4B
372.59%
40.39
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.3B
258.58%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.0B
172.77%
32.84
-4.74%

Insights on Ptc Therapeutics, Inc.

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 307.05M → 186.70M (in $), with an average decrease of 21.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -91.57M → -99.17M (in $), with an average decrease of 8.3% per quarter

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.7% return, outperforming this stock by 44.4%

Institutional Holdings

  • Vanguard Group Inc

    11.67%

  • Wellington Management Company LLP

    10.67%

  • BlackRock Inc

    10.10%

  • RTW INVESTMENTS, LLC

    9.61%

  • Armistice Capital, LLC

    9.05%

  • COWEN AND COMPANY, LLC

    4.88%

Corporate Announcements

  • Ptc Therapeutics, Inc. Earnings

    Ptc Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.

Organization
Ptc Therapeutics, Inc.
Employees
988
CEO
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Industry
Health Technology

Discover More

FAQs